Landec Corporation is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc.Landec designs, develops, manufactures and sells products for the food and biopharmaceutical industry. Curation Foods is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology. Curation Foods brands include Eat Smart® fresh packaged vegetables and salads, O Olive Oil & Vinegar® premium artisan products and Yucatan® and Cabo Fresh® avocado products. Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market.
Company profile
Ticker
LFCR
Exchange
Website
CEO
Albert Bolles
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LANDEC CORP \CA\
SEC CIK
Corporate docs
Subsidiaries
Curation Foods, Inc. • Lifecore Biomedical, Inc. ...
IRS number
943025618
LFCR stock data
Latest filings (excl ownership)
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
31 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Jan 23
8-K
Entry into a Material Definitive Agreement
9 Jan 23
NT 10-Q
Notice of late quarterly filing
9 Jan 23
8-K
Entry into a Material Definitive Agreement
25 Nov 22
8-K
Lifecore Biomedical Announces Completion of Corporate Name Change
16 Nov 22
8-K
Departure of Directors or Certain Officers
7 Nov 22
10-Q
2022 Q3
Quarterly report
7 Oct 22
8-K
Landec Corporation Reports First Quarter Fiscal Year 2023 Results
6 Oct 22
DEF 14A
Definitive proxy
19 Sep 22
Transcripts
LFCR
Earnings call transcript
2023 Q1
6 Oct 22
LFCR
Earnings call transcript
2022 Q4
11 Aug 22
LFCR
Earnings call transcript
2022 Q3
6 Apr 22
LFCR
Earnings call transcript
2022 Q2
6 Jan 22
LFCR
Earnings call transcript
2021 Q4
29 Jul 21
LFCR
Earnings call transcript
2021 Q3
8 Apr 21
LFCR
Earnings call transcript
2021 Q2
6 Jan 21
LFCR
Earnings call transcript
2021 Q1
7 Oct 20
LFCR
Earnings call transcript
2020 Q4
11 Aug 20
LFCR
Earnings call transcript
2020 Q3
31 Mar 20
Latest ownership filings
SC 13G/A
BlackRock Inc.
1 Feb 23
4
Raymond H Diradoorian
24 Jan 23
4
NELSON OBUS
18 Jan 23
SC 13D/A
WYNNEFIELD PARTNERS SMALL CAP VALUE LP
12 Jan 23
SC 13D
Cove Street Capital, LLC
12 Jan 23
4
Christopher S Kiper
11 Jan 23
3
Christopher S Kiper
11 Jan 23
4
NELSON OBUS
11 Jan 23
4
Nathaniel Calloway
11 Jan 23
3
Nathaniel Calloway
11 Jan 23
Financial summary
| Quarter (USD) | Aug 22 | May 22 | Feb 22 | Nov 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | May 22 | May 21 | May 20 | May 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 4.22 mm | 4.22 mm | 4.22 mm | 4.22 mm | 4.22 mm | 4.22 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 4.00 mm | 8.25 mm | 511.00 k | 2.23 mm |
| Cash used (since last report) | n/a | n/a | 20.75 mm | 42.79 mm | 2.65 mm | 11.57 mm |
| Cash remaining | n/a | n/a | -16.53 mm | -38.56 mm | 1.57 mm | -7.35 mm |
| Runway (months of cash) | n/a | n/a | -4.1 | -4.7 | 3.1 | -3.3 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 83 |
| Opened positions | 4 |
| Closed positions | 11 |
| Increased positions | 25 |
| Reduced positions | 30 |
| 13F shares | Current |
|---|---|
| Total value | 259.58 mm |
| Total shares | 30.39 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Wynnefield Capital | 3.53 mm | $31.41 mm |
| Legion Partners Asset Management | 2.94 mm | $26.14 mm |
| Wynnefield Partners Small Cap Value LP I | 2.51 mm | $26.01 mm |
| Iszo Capital | 1.93 mm | $0.00 |
| Cove Street Capital | 1.89 mm | $16.79 mm |
| Dimensional Fund Advisors | 1.83 mm | $16.30 mm |
| BLK Blackrock | 1.81 mm | $16.07 mm |
| 22NW Fund | 1.76 mm | $18.43 mm |
| 22NW | 1.76 mm | $15.60 mm |
| Iszo Capital Management | 1.53 mm | $13.61 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Jan 23 | Raymond H Diradoorian | Common Stock | Grant | Acquire A | No | No | 7 | 2,768 | 19.38 k | 2,768 |
| 20 Jan 23 | Raymond H Diradoorian | RSU Common Stock | Option exercise | Dispose M | No | No | 7 | 2,768 | 19.38 k | 0 |
| 9 Jan 23 | Nathaniel Calloway | RSU Common Stock | Grant | Acquire A | No | No | 0 | 5,906 | 0.00 | 5,906 |
| 9 Jan 23 | Wynnefield Partners Small Cap Value LP I | Series A Convertible Preferred Stock Common Stock | Buy | Acquire P | Yes | No | 1000 | 650 | 650.00 k | 650 |
| 9 Jan 23 | Wynnefield Partners Small Cap Value LP I | Series A Convertible Preferred Stock Common Stock | Buy | Acquire P | Yes | No | 1000 | 1,040 | 1.04 mm | 1,040 |
| 9 Jan 23 | Wynnefield Partners Small Cap Value LP I | Series A Convertible Preferred Stock Common Stock | Buy | Acquire P | No | No | 1000 | 1,560 | 1.56 mm | 1,560 |
News
Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
19 Jan 23
Lifecore Biomedical Receives Notice From Nasdaq Regarding Delayed Quarterly Report
11 Jan 23
Lifecore Biomedical Raises Capital With $38.75M Private Placement Of Convertible Preferred Stock; Amends Credit Facilities
9 Jan 23
Stocks That Hit 52-Week Lows On Thursday
5 Jan 23
4 Cheapest Defensive Stocks You Should Think About
5 Jan 23
Press releases
Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report
11 Jan 23
Lifecore Biomedical Raises Capital with Private Placement of Convertible Preferred Stock; Amends Credit Facilities
9 Jan 23
Lifecore Biomedical Raises Capital for Growth with Existing Stockholder
25 Nov 22
Lifecore Biomedical Announces Completion of Corporate Name Change
14 Nov 22
Lifecore Biomedical to Participate in the Stephens Annual Investment Conference on Thursday, November 17, 2022
10 Nov 22